A re-examination of the use of ethnicity in prenatal carrier testing

American Journal of Medical Genetics, Part A

Volumn 158 A, Issue 1, 2012, Pages 19-23

  Ross, Lainie Friedman ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Carrier testing; Cystic fibrosis; Ethnicity; Heterozygote detection; Prenatal testing; Sickle cell disease; Tay Sachs disease

Indexed keywords

ANAMNESIS; ARTICLE; CHILD HEALTH CARE; CLINICAL DECISION MAKING; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DNA DETERMINATION; EARLY DIAGNOSIS; ETHNICITY; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HEMOGLOBINOPATHY; HETEROZYGOTE; HUMAN; LABORATORY TEST; NEWBORN SCREENING; PATIENT CODING; POPULATION GENETICS; PRACTICE GUIDELINE; PRENATAL SCREENING; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SICKLE CELL ANEMIA; TAY SACHS DISEASE;

ANEMIA, SICKLE CELL; CYSTIC FIBROSIS; FEMALE; GENETIC TESTING; GYNECOLOGY; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; JEWS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PRENATAL DIAGNOSIS; TAY-SACHS DISEASE;

EID: 84255188972     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.34361     Document Type: Article

References (40)

1. ACMG/HRSA. American College of Medical Genetics (ACMG)/Health Resources and Services Administration (HRSA). 2006. Newborn Screening: Toward a Uniform Screening Panel and System. Last accessed July 30, 2011.
2. ACOG. American College of Obstetrics and Gynecology (ACOG) Committee on Genetics. 2005a. Screening for Tay-Sachs disease. Obstetr Gynecol 106: 893-894.
3. ACOG. American College of Obstetrics and Gynecology (ACOG) Committee on Genetics. 2005b. Update on carrier screening for cystic fibrosis. Obstetr Gynecol 106: 1465-1468.
4. ACOG. American College of Obstetricians and Gynecologists Committee on Genetics. 2011. ACOG Committee Opinion 46. Update on carrier screening for cystic fibrosis. Obstetr Gynecol 117: 1028-1031.
5. ACOG. American College of Obstetrics and Gynecology (ACOG) Committee on Practice Bulletins. 2007. ACOG Practice Bulletin Number 78: Hemoglobinopathies in pregnancy. Obstetr Gynecol 109: 229-237.
6. ACOG/ACMG. American College of Obstetricians and Gynecologists (ACOG) American College of Medical Genetics (ACMG). 2001. Preconception and prenatal carrier screening for cystic fibrosis: Clinical and laboratory guidelines. Washington, DC: ACOG, ACMG. pp. 1-32.
7. Andrews LL, Fullarton JE, Holtzman NA, Motulsky AG, editors, and the Committee on Assessing Genetic Risks, Institute of Medicine (IOM). 1994. Assessing genetic risks: Implications for health and social policy. Washington DC: National Academy Press.
8. Aspinall PJ, Dyson SM, Anionwu EN. 2003. The feasibility of using ethnicity as a primary tool for antenatal selective screening for sickle cell disorders: Pointers from the research evidence. Soc Sci Med 56: 285-297.
9. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF. 2011. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Translat Med 3: 65ra4.
10. Benson JM, Therrell BL Jr. 2010. History and current status of newborn screening for hemoglobinopathies. Semin Perinat 34: 134-144.
11. Branda KJ, Tomczak J, Natowicz MR. 2004. Heterozygosity for Tay-Sachs and Sandhoff diseases in non-Jewish Americans with ancestry from Ireland, Great Britain, or Italy. Genet Test 8: 174-180.
12. Castellani C, Massie J. 2010. Emerging issues in cystic fibrosis newborn screening. Curr Opin Pulm Med 16: 584-590.
13. Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Ferec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek M, Mehta G Jr., Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooij A, Elborn S. 2009. European best practice guidelines for cystic fibrosis neonatal screening. J Cystic Fibr 8: 153-173.
14. Cronin EK, Normand C, Henthorn JS, Hickman M, Davies SC. 1998. Costing model for neonatal screening and diagnosis of haemoglobinopathies. Archiv Dis Child Fetal Neonat Ed 79: F161-F167.
15. Dyson SM, Culley L, Gill C, Hubbard S, Kennefick A, Morris P, Rees D, Sutton F, Squire P. 2006. Ethnicity questions and antenatal screening for sickle cell/thalassaemia [EQUANS] in England: A randomized controlled trial of two questionnaires. Ethnic Health 11: 169-189.
16. Elias S, Annas GJ. 1994. Generic consent for genetic screening. New Engl J Med 330: 1611-1613.
17. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, et al. for the Penicillin Prophylactic Study Group. 1986. Prophylaxis with oral penicillin in children with sickle cell anemia: A randomized trial. New Engl J Med 314: 1593-1599.
18. Gessner BD, Teutsch SM, Shaffer PA. 1996. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems. Early Hum Develop 45: 257-275.
19. Grosse SD. 2010. What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to say. Am J Obstet Gynecol 202: 209-211.
20. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM. 2010. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inher Metab Dis 33: S255-S261.
21. Hinton CF, Grant AM, Grosse SD. 2011. Ethical implications and practical considerations of ethnically-targeted screening for genetic disorders: The case of hemoglobinopathy screening. Ethnic Health 16: 377-388.
22. Kaback MM. 2001. Screening and prevention in Tay-Sachs disease: Origins, update and impact. Adv Genet 44: 253-265.
23. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. for The International TSD Data Collection Network. 1993. Tay-Sachs disease: carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. JAMA 270: 2307-2315.
24. Kadkhodaei Elyaderani M, Cinkotai KI, Hyde K, Waters HM, Howarth J, Goldstone S, Richards JT. 1998. Ethnicity study and non-selective screening for haemoglobinopathies in the antenatal population of central Manchester. Clin Lab Haemat 20: 207-211.
25. Korzeniewski SJ, Young WI, Hawkins HC, Cavanagh K, Nasr SZ, Langbo C, Teneyck KR, Grosse SD, Kleyn M, Grigorescu V. 2011. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening. Pediatr Pulm 46: 125-130.
26. Langfelder-Schwind E, Kloza E, Sugarman E, Pettersen B, Brown T, Jensen K, Marcus S, Redman J. National Society of Genetic Counselors Subcommittee on Cystic Fibrosis Carrier Testing. 2005. Cystic fibrosis prenatal screening in genetic counseling practice: Recommendations of the National Society of Genetic Counsellors. J Genet Counsel 14: 1-15.
27. Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. 2010. The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol 202: 253.e1-253.e7.
28. Montalvo AL, Filocamo M, Vlahovicek K, Dardis A, Lualdi S, Corsolini F, Bembi B, Pittis MG. 2005. Molecular analysis of the HEXA gene in Italian patients with infantile and late onset Tay-Sachs disease: detection of fourteen novel alleles. Hum Mutat 26: 282. On line at: Last accessed July 30, 2011.
29. National Newborn Screening and Genetics Resource Center (NNSGRC). 2011. National Newborn Screening Status Report Updated 07/28/11. On the web at: Last accessed July 30, 2011.
30. NIH. National Institutes of Health. 1987. Consensus Development Panel. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 258: 1205-1209.
31. Ormond KE, Iris M, Banuvar S, Minogue J, Annas GJ, Elias S. 2007. What do patients prefer: Informed consent models for genetic carrier testing. J Genet Counsel 16: 539-550.
32. Panepinto JA, Magid D, Rewers MJ, Lane PA. 2000. Universal versus targeted screening of infants for sickle cell disease: A cost-effectiveness analysis. J Pediatr 136: 201-208.
33. Phillips B. Undated. National Jewish Population Survey: 1990. Fifty-two percent intermarriage rate shocks community. On the web at: Last accessed July 30, 2011.
34. Pletcher BA, Gross SJ, Monaghan KG, Driscoll DA, Watson MS. 2008. The future is now: carrier screening for all populations. Genet Med 10: 33-36.
35. Roberts S. 2010. Census Figures Challenge Views of Race and Ethnicity. The New York Times. January 21, 2010. On the web at: Last accessed July 30, 2011.
36. Ross LF. 2008. Newborn Screening for Cystic Fibrosis: A Lesson in public health disparities. J Pediatr 153: 308-313.
37. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. 2005. Meeting minutes from January 13-14, 2005. On the web at: Last Accessed October 22, 2011.
38. Shafer FE, Lorey F, Cunningham GC, Klumpp C, Vichinsky E, Lubin B. 1996. Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. J Pediatr Hem/Onc 18: 36-41.
39. Sprinkle RH, Hynes DM, Konrad TR. 1994. Is universal neonatal hemoglobinopathy screening cost effective? Archiv Pediatr Adol Med 148: 461-469.
40. Wilfond BS, Gollust GE. 2005. Policy issues for expanding newborn screening programs: The cystic fibrosis newborn screening experience in the Untied States. J Pediatr 146: 668-674.